NCT00220129已完成2 期
Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized Squamous Cell Carcinoma of the Oesophagus
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- 2 year overall survival
研究概览
简要总结
This is a study to investigate the efficacy and safety of epirubicin, cisplatin and capecitabine (ECX) as neoadjuvant therapy prior to radical chemoradiotherapy using capecitabine and cisplatin as radio-sensitisers in patients with newly diagnosed localized squamous cell carcinoma of the oesophagus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years.
- •Histologically verified squamous cell carcinoma of the cervical or thoracic oesophagus
- •American Joint Committee on Cancer (AJCC) Stage I-III (T1-3 N0-1 M0) (33), as assessed by spiral or multi-slice computed tomography (CT) and endoscopic ultrasound, where radical chemoradiation would be considered with curative intent.
- •No previous chemotherapy, radiotherapy or other investigational drug treatment for this indication.
- •World Health Organization (WHO) performance status 0,1 or
- •Adequate bone marrow function with platelets > 100 x 10^9/l; white blood cells (WBC) > 3 x 10^9/l; neutrophils > 1.5 x 10^9/l at the time of study entry.
- •Serum bilirubin < 35 micromol/l.
- •Serum creatinine < 180 micromol/l and measured creatinine clearance over 60 ml/min.
- •No concurrent uncontrolled medical condition.
- •No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix in the last 10 years.
- •Life expectancy > 3 months.
- •Adequate contraceptive precautions if relevant.
- •Informed written consent.
排除标准
- •The presence of locally advanced or metastatic disease precluding curative chemoradiation (T4 or Stage IV or M1a-b) or disease not encompassable in a radical radiotherapy field.
- •Total dysphagia (O'Rourke's swallowing function scoring system 5) precluding swallowing of capecitabine even when crushed.
- •Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
- •Intracerebral metastases or meningeal carcinomatosis.
- •New York Heart Association classification Grade III or IV.
- •Uncontrolled angina pectoris.
- •Pregnancy or breast feeding.
- •Impaired renal function with measured creatinine clearance less than 60 ml/min.
- •Previous investigational study drug
- •Known malabsorption syndromes
- •Patients with a known hypersensitivity to fluorouracil (5-FU) or with a dihydropyrimidine dehydrogenase (DPD) deficiency
- •Hearing loss
结局指标
主要结局
2 year overall survival
次要结局
- Objective clinical response rate assessed by computed tomography (CT), endoscopic ultrasound (EUS) and endoscopic biopsy
- Pattern of treatment failure
- Progression free survival
- Proportion of patients not achieving clinical complete response and requiring surgery after chemoradiation
- Treatment related toxicity
- Time to improvement of dysphagia
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal AdenocarcinomaAdenocarcinoma of OesophagusNCT00220103Royal Marsden NHS Foundation Trust80
已完成
1 期
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic CancerExtrahepatic Bile Duct CancerGallbladder CancerUnspecified Adult Solid Tumor, Protocol SpecificGastric CancerLiver CancerNCT00486356University of Nebraska46
终止
1 期
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast CancerHER-2 Positive Breast CancerNCT01388647Vector Oncology12
已完成
2 期
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast CancerBreast CancerNCT00645866Mayo Clinic47
进行中（未招募）
不适用
?Fase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide ? trastuzumab as preoperative treatment of locally advanced ER and PgR negative breast cancer?. - NDocally advanced breast cancerMedDRA version: 12.0Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2009-012048-18-ITISTITUTO EUROPEO DI ONCOLOGIA